#### Proteomics Uncovers Immunosuppression in COVID-1

2

## **19 Patients with Long Disease Course**

- Shaohua Tang <sup>1#</sup>, Rui Sun <sup>2,3#</sup>, Qi Xiao <sup>2,3#</sup>, Tingting Mao <sup>1#</sup>, Weigang Ge <sup>2,3#</sup>, 3
- 4 Chongquan Huang <sup>1#</sup>, Meng Luo <sup>2,3,4</sup>, Liujia Qian <sup>2,3</sup>, Hao Chen <sup>2,3</sup>, Qiushi Zhang <sup>2,3</sup>,
- Sainan Li<sup>2,3</sup>, Wei Liu<sup>2,3,5</sup>, Shufei Li<sup>1</sup>, Xuegin Xu<sup>1</sup>, Huanzheng Li<sup>1</sup>, Lianpeng Wu<sup>1</sup>, 5
- Jianyi Dai<sup>1</sup>, Huanhuan Gao<sup>2,3</sup>, Lu Li<sup>2,3</sup>, Tian Lu<sup>2,3</sup>, Xiao Liang<sup>2,3</sup>, Xue Cai<sup>2,3</sup>, Guan 6
- Ruan <sup>2,3</sup>, Kexin Liu <sup>4</sup>, Fei Xu <sup>5</sup>, Yan Li <sup>6</sup>, Yi Zhu <sup>2,3</sup>\*, Jianping Huang <sup>1</sup>\*, Tiannan Guo 7 2,3,7\*
- 8
- 9 <sup>1</sup> Wenzhou Central Hospital, Dingli Clinical Medical School of Wenzhou Medical University,
- Wenzhou, 325000, Zhejiang, China; 10
- 11 <sup>2</sup> Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences,
- Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China; 12
- <sup>3</sup> Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan 13
- 14 Road, Hangzhou 310024, Zhejiang Province, China;
- 15 <sup>4</sup> Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University,
- 16 Dalian 200335, Liaoning, China
- 17 <sup>5</sup> Department of Anatomy, College of Basic Medical, Dalian Medical University, Dalian, China
- 18 <sup>6</sup> Department of Anatomy and Physiology, College of Basic Medical Sciences, Shanghai Jiao
- 19 Tong University, No.280 Chongqing South Road, Shanghai 200025, China
- <sup>7</sup>Lead Contact 20
- <sup>#</sup> These authors contribute equally 21
- 22 \* Correspondence: <u>zhuyi@westlake.edu.cn</u> (Y.Z.); <u>hipzxyy006@163.com</u> (J.H.);
- 23 guotiannan@westlake.edu.cn (T.G.)
- 24

#### Abstract 25

26 Little is known regarding why a subset of COVID-19 patients exhibited prolonged positivity of SARS-CoV-2 infection. Here, we present a longitudinal 27 sera proteomic resource for 37 COVID-19 patients over nine weeks, in which 28 2700 proteins were quantified with high quality. Remarkably, we found that 29 during the first three weeks since disease onset, while clinical symptoms and 30 outcome were indistinguishable, patients with prolonged disease course 31 displayed characteristic immunological responses including enhanced Natural 32 Killer (NK) cell-mediated innate immunity and regulatory T cell-mediated 33 immunosuppression. We further showed that it is possible to predict the 34 length of disease course using machine learning based on blood protein 35 levels during the first three weeks. Validation in an independent cohort 36 achieved an accuracy of 82%. In summary, this study presents a rich serum 37 38 proteomic resource to understand host responses in COVID-19 patients and 39 identifies characteristic Treg-mediated immunosuppression in LC patients, nominating new therapeutic target and diagnosis strategy. 40

41 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 42 **INTRODUCTION**

COVID-19 caused by the SARS-CoV-2 virus is an ongoing pandemic 43 spreading all over the world. About 80% of COVID-19 patients exhibit mild 44 clinical symptoms including fever and cough, while ~20% of patients 45 deteriorate to life-threatening severe or critical conditions (Wu and 46 McGoogan, 2020). Multiple studies have investigated the clinical course and 47 pathogenesis (To et al., 2020; Yang et al., 2020; Zhou et al., 2020) and 48 molecular changes (Messner, 2020; Shen, 2020; Wu et al., 2020) of severe or 49 critical cases. 50

51 What remains largely unknown is the substantial diversity of COVID-19 patients in terms of disease course. In a recent report, the median interval of 52 53 COVID-19 patients from onset to clinical recovery was 20 days, with the longest disease course of 37 days (Zhou et al., 2020). According to our 54 clinical treatment of 37 COVID-19 patients, some patients exhibited 55 surprisingly prolonged virus infection. The longest disease course we have 56 observed thus far is 107 days (P33, a 55-year-old male) as of 17 May 2020. 57 Little is known about the causes of persistent virus infection and how he could 58 be effectively treated. 59

Here we report a longitudinal and in-depth proteomic profiling of 37 60 COVID-19 patients with short and long disease courses. We analyzed the 61 sera proteomes collected over nine weeks for both patients with short disease 62 course (SC) who turned negative for the virus infection in less than 22 days, 63 and LC patients who remained positive for 22 days or longer. We have also 64 analyzed the sera proteomes of 35 non-COVID-19 patients with flu-like 65 symptoms as controls. 2700 proteins were quantified with high quality, offering 66 a rich resource to understand the dynamic disease course of COVID-19 67 patients in response to virus infection. Our data showed characteristic 68 69 immune responses between the SC and LC patient groups. Remarkably, the data suggest regulatory T cell (Treg)-mediated immunosuppression was 70 specifically activated in LC patients. We also showed that it is possible to 71 predict the disease course of COVID-19 patients by measuring the 72 characteristic protein levels from blood samples collected in the first three 73 weeks since disease onset using a machine learning model. This study not 74 only presents a rich resource to study the COVID-19 host responses, but also 75 nominates novel therapeutic and diagnostic strategies for COVID-19 patients 76 with prolonged infection positivity. 77

78

## 79 RESULTS AND DISCUSSION

#### 80 Patients, samples and proteomics

We procured 37 COVID-19 patients in this study of which 35 were typical and two were severe cases (Table 1, Table S1), including 19 males and 18 females, with a median age of 48 years. The median duration of disease in this cohort, as defined in Methods, was 22 days. These patients were divided
into two groups based on the length of their disease course (Figure 1). The
SC group comprised 17 patients with a disease course shorter than 22 days.
The other 20 patients were defined as LC group. Interestingly, one of the
severe cases was classified as SC, while the other severe case was in the LC
group (Figure 1).

These two groups (SC and LC) were indistinguishable based on clinical 90 symptoms. The median age of SC patients was 43.2 years (range, 27-67 91 vears) for SC patients, and 49.0 years (range, 2-84 years) for LC patients. 92 The Wilcox t-test showed no significant age difference between the SC and 93 LC patient groups (Figure S1A). Clinical treatment of both groups of patients 94 was not significantly different by Fisher's exact test (Figure S1B, Table 1), 95 indicating that the different lengths of disease course were unlikely due to 96 existing therapeutics. Routine blood test data for the two groups showed no 97 significant difference either (Figure S1C). We analyzed an additional 35 non-98 COVID-19 patients with flu-like symptoms as controls (Table 1, Table S1, and 99 Figure 1B). 100

101 We performed in-depth profiling for sera proteome collected from each patient over nine weeks using TMTpro 16plex-based data-dependent 102 acquisition mass spectrometry (Thompson et al., 2019). 14 high-abundance 103 blood proteins were largely depleted to enhance the ability to measure low-104 abundance proteins. Each TMT-labeled peptide mixture was fractionated into 105 26-30 fractions for comprehensive discovery proteomic analysis (Figure 1A). A 106 total of 224 depleted serum samples were analyzed using TMT-based 107 proteomics (Figure 1). Samples were randomly distributed into 18 batches. 108 We also analyzed 44 technical replicates for randomly selected samples oin 109 each batch (Figure S2A). Each pool of TMT-labeled peptides was further 110 fractionated into 26-30 fractions using high-pH reverse phase liquid 111 chromatography (RPLC) and analyzed by LC-MS/MS using a 60-min RPLC 112 gradient. The median coefficient of variance (CV) among MS/MS technical 113 replicates was 0.19 (Figure S2B). After excluding proteins with missing values 114 in over 80% of samples, we presented quantitative levels of 2700 proteins 115 across 268 sera samples with relatively high degrees of quantitative accuracy 116 117 (Table S2A).

118

### 119 **Complex immunity in the LC patients**

To investigate host response differences in the serum proteome data set 120 from the SC and LC patients, we performed a pairwise comparison of the 121 proteins guantified in these two groups at each week over nine weeks. We 122 then combined the regulated proteins at each week, leading to the 123 124 identification of 921 dysregulated proteins (Table S2B), of which 405 proteins 125 were functionally annotated in the UniProt database. We firstly used only GO biological process, KEGG and Reactome pathway enrichment using 405 126 proteins, and found that most pathways were related to immunity and 127

128 metabolism (Figure S3).

Generally, our data showed that the first week is the inflammatory 129 response period, featured by activation of redox and amino acid metabolic 130 processes. In the following three weeks, more pathways involved in adaptive 131 immunity and glycometabolism were activated. Interestingly, some sex 132 hormone associated pathways were also enriched, such as fertilization and 133 response to estradiol. From fifth to ninth week, the two patient groups 134 displayed difference in pathways involved in tissue remodelling and repair, 135 apoptosis and sulfur compound catabolic process. 136

We then focused on the immunity-related pathways at each time point as 137 shown in Figure 2A. For SC patients, they showed upregulated platelet 138 degranulation in the first week, followed by activation of antigen presentation 139 140 in the following two weeks. Leukocyte degranulation was activated in the third week. In the sixth week, SC patients showed upregulation of serum proteins 141 involved in tissue remodeling (Figure 2A) as signs of recovery. LC patients 142 displayed much more complex serum proteome dynamics. During the first 143 week, both platelet degranulation and upregulation of Treg vs Teff were 144 activated. Activation of antigen presentation occurred in the second week. The 145 complement system was also activated from the second week. Interestingly, 146 the regulatory T cell (Treg) activation pathway was enriched in the first two 147 weeks and the fifth week, suggesting immunosuppression occurred early in 148 these patients. From the fourth week, leukocyte migration was enriched. 149 Tissue repair was enriched only in the eighth week, followed by the 150 complement system in the ninth week (Figure 2A). These data suggest that 151 immunological responses during the first three weeks may be critical in 152 determining the length of the disease course. During this period, both innate 153 and adaptive immunity were activated in SC patients, while in contrast, LC 154 patients showed signs of Treg-mediated immunosuppression in addition to 155 156 innate and adaptive immunity.

Our data also underscored the proteins involved in the above-mentioned 157 pathways as shown in Figure S3. In SC patients, a secreted protein, the 158 soluble scavenger receptor cysteine-rich domain-containing protein (SSC5D) 159 was highly expressed in the second week (Figure S4). SSC5D is highly 160 expressed on monocytes and activated lymphocytes rather than naïve 161 immune cells, and mediates both innate and adaptive immunity (Goncalves et 162 al., 2009), suggesting activated immune responses to virus infection. In the 163 third week, another upregulated protein in SC patient sera was non-secretory 164 ribonuclease (RNASE2), a chemoattractant for dendritic cells. RNASE2 is 165 reported to participate in antigen presentation (Yang et al., 2003), and may 166 play a role in the adaptive immunity against SARS-CoV-2 (Figure S4). In the 167 fourth week, a pro-inflammatory factor, chromogranin-A (CHGA), was 168 upregulated in the sera in SC patients. CHGA highly expressed on the 169 secretory cells to regulate catecholamine secretion which is associated with 170 serum CHGA (di Comite et al., 2006) and is reported to activate pro-171

inflammatory M1 macrophages and inhibit anti-inflammatory M2 macrophages
(Eissa et al., 2018). In the sixth week, serum amyloid P-component (APCS)
was upregulated in SC patient sera (Figure S4), suggesting clearance of
damaged circulating cells and enhanced angiogenesis.

In LC patients, positive regulators for immune response were found to be 176 activated. Hepatocyte growth factor-like protein (MST1) was upregulated in 177 the second week (Figure 2A). MST1 is required for thymocyte migration and 178 antigen recognition (Ueda et al., 2012). Besides, Golgi-associated plant 179 pathogenesis related protein 2 (GLIPR2), associated with the migration of T 180 and B lymphocytes, was up-regulated in the fourth week (Figure S4). In the 181 following week, we observed upregulation of two immunosuppressive factors, 182 namely fibroleukin (FGL2) and programmed cell death 1 ligand 2 183 184 (PDCD1LG2). FGL2 negatively regulates dendritic cell antigen presentation and T cell differentiation, especially the secreted FGL2 (Hu et al., 2016). It 185 was upregulated in LC patients and further increased during recovery from 186 COVID-19 (Figure S4). PDCD1LG2 negatively regulates T cell activation 187 (Brown et al., 2003), and followed similar dynamics over the disease course to 188 FGL2 (Figure S4). In the eighth week, tissue remodeling associated proteins, 189 such as von Willebrand factor (VWF), were upregulated in the LC group, 190 suggesting recovery from COVID-19. Besides, our data show that the 191 complement system may play important roles in LC patients during the entire 192 disease course. In the second week, the most enriched pathway involving the 193 upregulation of C5 was the complement cascade (Figure 2A). In the last 194 week, C8A and other complement system proteins remained upregulated 195 (Figure S4). Complement activation was reported in our previous study of 196 COVID-19 sera (Shen, 2020). The complement cascade could also contribute 197 to immunosuppression (Kemper et al., 2003) and might be a potential 198 therapeutic target for COVID-19 (Cao, 2020). 199

Altogether, negative regulator factors and innate immune performed more active might result in longer disease course.

202 203

### Characteristic protein dynamics in the LC patients

Next, we investigated whether the differentially expressed proteins 204 between SC and LC patients were unique to COVID-19 disease by making 205 comparison between COVID-19 and non-COVID-19 patients with flu-like 206 symptoms (Ctrl, Figure 1B). We first analyzed the temporal dynamics of the 207 2700 proteins using Mfuzz (Kumar and Mattias, 2007) for SC and LC patients. 208 1746 proteins, grouped in eight clusters in the SC and LC patient groups 209 (Table S2C), were consistently dysregulated over time compared to the 210 control group (Figure S5A-B). Four characteristic protein clusters were 211 enriched in the two patient groups (Figure S5C). In the meantime, 774 212 213 proteins were identified to be differentially expressed in COVID-19 patients compared to the Ctrl group (Table S2D). By overlapping the two above-214 mentioned protein shortlists with the 921 dysregulated proteins between SC 215

and LC patients, our data were narrowed down to 207 proteins which fulfill the
following three criteria: a) differentially expressed between SC and LC; b)
consistently up- or down-regulated over time; c) COVID-19 disease specific
(Figure 2B). Out of 207 proteins, 97 proteins were functionally annotated by
the Ingenuity Pathway Analysis (IPA) software tool (Table S2E).

These proteins were segregated into two major groups based on their 221 expression across all nine time points during the disease course (Figure 2C). 222 The first group of 80 proteins showed increased expression over time. SC 223 patients exhibited earlier elevation of these proteins, while LC patients 224 exhibited delayed increase (Figure 2C). Four major pathways were enriched 225 in this protein group, namely acute phase response, LXR/RXR activation, 226 agranulocyte adhesion and diapedesis, and actin cytoskeleton signaling 227 228 (Figure 2D). Also, the coagulation and complement systems were also enriched in this protein group. Acute phase response signaling, coagulation 229 and complement systems are associated with innate immunity, while actin 230 cytoskeleton signaling is associated with leukocyte migration in adaptive 231 232 immunity.

The second group of 17 proteins showed decreasing expression over time. SC patients showed an earlier decrease than LC patients (Figure 2E). These proteins were mapped to enriched pathways including metabolic processes such as myo-inositol biosynthesis, glycolytic shunt and glutamyl cycle (Figure 2E).

Next, we calculated the median expression level of the two groups of 238 proteins and present them in boxplots (Figure 2D, 2E). For the first group of 239 proteins, generally SC patients showed lower protein expression than LC 240 patients in the first three weeks, but the expression was dramatically elevated 241 from the fourth week and maintained thereafter at a high level for several 242 weeks (Figure 3D). This agrees with clinical data that all these SC patients 243 244 tested negative for SARS-CoV-2 nucleic acid after the third week. In contrast, 245 LC patients showed a higher degree of longitudinal diversity in the trends of expression of these proteins, probably partly due to their variable clinical 246 recovery trajectories. Expression of the first group of proteins in the first four 247 weeks was relatively stable but dramatically increased in the fifth week. 248 249 followed by a decrease from the sixth to the seventh week, and a second rise in the eighth week (Figure 2D). 250

Interestingly, the expression of the second group of proteins displayed an opposite trend compared to the first group (Figure 2E). Protein expression of the SC patients started to decrease during the 4<sup>th</sup> week and continued to decrease until the last time point; while the LC patients showed high protein expression level till the fifth week, with a shallow decrease beginning in the sixth week (Figure 2E).

257 258

259

#### Dysregulated leukocyte migration and IFG/redox homeostasis

Pathway analysis of the two protein groups mentioned above highlighted

leukocyte migration and IGF/redox homeostasis (Figure 3).

Representative proteins related to leukocyte migration included beta-261 defensin 1 (DEFB1), selectin P (SELP), ezrin (EZR) and moesin (MSN) 262 (Figure 3A). DEFB1 is a ligand for the chemokine receptor CCR6 and a 263 positive upstream regulator of Th17 (Wojtowicz et al., 2015). SC patients 264 exhibited high expression of DEFB1 in the first three weeks, but it decreased 265 from the fourth week when patients became negative in the nucleic acid test 266 (Figure 3A). In contrast, LC patients exhibited a delayed increase of this 267 protein until the third week (Figure 3A), suggesting delayed activation of Th17 268 in LC patients. Leukocyte extravasation occurs in two sequential steps, 269 among which SELP participates in the first process of leukocyte adhesion to 270 the endothelial surface (Vicente-Manzanares and Sanchez-Madrid, 2004). In 271 272 SC patients, expression of SELP was relatively low in the first three weeks, and then increased significantly in the fourth week and maintained at a high 273 level until the ninth week (Figure 3A). SELP increase in LC patients, however, 274 was much shallower, and peaked as late as the eighth week, in line with their 275 prolonged disease course (Figure 3A). The complex of ezrin-radixin-moesin 276 (ERM) links cytoskeleton with membrane adhesion molecules: however. 277 moesin (MSN) and ezrin exert opposite functions (Ivetic et al., 2002). Our data 278 showed that EZR was maintained at a relatively high level during the first 279 three weeks in SC patients and then decreased thereafter (Figure 3A). 280 Interestingly, in these patients, MSN showed an opposite trend in which 281 expression increased from the fourth week and thereafter was maintained at a 282 relatively high level. In LC patients, the change of ERM components showed a 283 similar pattern but with a delayed transition point (Figure 3A). 284

In addition to the proteins directly involved in immunity, our data also 285 highlighted metabolic pathways such as the IGF/redox homeostasis pathway 286 which is critical in maintaining the microenvironment for immune responses 287 (Figure 3A). We narrowed our focus to proteins involved in IGF/redox 288 289 homeostasis namely insulin-like growth factor 1 (IGF1), superoxide dismutase (SOD1), glutathione synthetase (GSS) and 5-oxoprolinase (OPLAH) (Figure 290 3A). IGF1 promotes the proliferation of Treg cells (Anguela et al., 2013). In SC 291 patients, expression of IGF1 increased from the second to the sixth week, 292 293 followed by a dramatic decrease in the seventh week, in line with the recovery of these patients (Figure 3A). However, in LC patients, expression of IGF1 294 slightly upregulated than in SC patients and increased until the eighth week, 295 followed by a slow decline thereafter. The expression of IGF1 is higher in the 296 LC patients than SC patients in the initial and the end of the disease stage 297 (Figure 3A). Infection-induced ROS was reported to accelerate the 298 accumulation of Treg cells, which led to immunosuppression (Yang et al., 299 2013). ROS may also induce the expression of SOD1 in the mitochondria to 300 reduce ROS as negative feedback (Ma, 2013). Our data showed that the 301 expression of SOD1 peaked earlier in SC patients (fourth week) than that in 302 the LC patients (fifth week, Figure 4A), indicating that clearance of infection-303

induced ROS in SC patients occurred earlier than in LC patients. GSS and 304 OPLAH are both involved in the glutamyl cycle that maintains redox 305 homeostasis (Forman et al., 2009). In the glutamyl cycle, GSS catalyzes the 306 generation of reduced glutathione (GSH). OPLAH catalyzes the conversion of 307 5-oxoproline into glutamate and indirectly enhances the consumption of GSH. 308 Our data showed that GSS was upregulated in the fourth week in SC patients, 309 about one week earlier than its increase in LC patients (Figure 3A). In 310 contrast, the downregulation of OPLAH began in the fourth week in SC 311 patients, while in LC patients it did not substantially decrease until the eighth 312 week (Figure 3A). The timely upregulation of GSS and downregulation of 313 OPLAH might contribute to the elimination of infection-induced ROS in SC 314 patients, while their delayed modulation may have contributed to the 315 316 prolonged disease course of LC patients.

317

318

#### Treg-mediated immunosuppression and crosstalk with other immune cells in the LC patients 319

320 The leukocyte migration and IGF/redox homeostasis pathway may 321 modulate the activities of Th17 and Treg cells (Figure 3B). Th17 cells are a subset of T helper (Th) cells. Th17 cells are differentiated from CD4+ T cells 322 with a pro-inflammatory role upon infection when IL6 is relatively high (Kimura 323 and Kishimoto, 2010). The upregulation of IL-6 has been reported as one of 324 the most critical cytokines in severe COVID-19 patients (Ruan et al., 2020). 325 Our data suggested that activation of Th17 cells may play a role in T cell 326 immunity in COVID-19. Opposite to Th17 cells, Treg cells are induced from 327 CD4+ T cells when IL-6 is relatively low and they suppress immunity (Kimura 328 and Kishimoto, 2010). 329

Our data showed longitudinal down-regulation of DEFB1, an upstream 330 activator of Th17. LC patients showed a delayed decrease of DEFB1, 331 suggesting delayed activation of Th17. IGF1 promotes Treg cells. A higher 332 333 level of IGF1 in the LC patients suggested aberrant Treg-mediated immunosuppression in the LC patients (Figure 3A). Besides, infection-induced 334 ROS, regulated by GSS and OPLAH, may also trigger Treg-mediated 335 immunosuppression in LC patients as discussed above. 336

337 We next applied flow cytometry to analyze the CD127 CD25<sup>+</sup> Treg cell subpopulation in peripheral blood samples collected from disease onset to the 338 fourth week (SC: 17 patients, 30 samples; LC: 17 patients, 22 samples). The 339 data showed that the number of CD127<sup>-</sup>CD25<sup>+</sup> Treg cells was significantly 340 higher in LC patients than that in SC patients (p=0.006), while the CD45<sup>+</sup> 341 lymphocytes (p=0.306) and CD3<sup>+</sup>CD4<sup>+</sup> T cells (p=0.871) did not show a 342 significant difference (Figure 4A). The data support the hypothesis that 343 344 CD127<sup>-</sup>CD25<sup>+</sup> Treg-mediated immunosuppression may be induced in LC 345 patients during the first few weeks. Inhibition of Treg cells could be a potential therapeutic approach for COVID-19 patients with long disease course. 346 More natural killer (NK) cells, especially the cytotoxic subset (CD3-347

CD56<sup>+</sup>CD16<sup>+</sup>), were found in LC patients (Figure 4B). NK cells are a typical 348 kind of cells in innate immunity. In the meantime, CD3<sup>-</sup>CD56<sup>-</sup>CD16<sup>-</sup> cells were 349 found to be decreased in the LC group (Figure S6A-B). These cells are 350 probably B cells, which is further supported by our finding that the antibody 351 level of these patients were also decreased (Huang, 2020). The decrease of B 352 cells may also be supported by the finding that NK cells can inhibit the B cell 353 immunity through reducing neutralizing antibodies (Rydyznski et al., 2015). 354 However, unfortunately we did not have sufficient sample to stain these 355 reduced cells with markers for B cells to confirm their identity. 356

We then measured the key cytokines and growth factors such as IL-2, IL-357 4, IL-5, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α of clinical importance. They 358 were measured using antibody-based method (SC: 17 patients, 30 samples: 359 360 LC: 17 patients, 22 samples; Figure 5B and Figure S6C). Except for TNF- $\alpha$ , other molecules showed no difference between SC and LC patients, probably 361 because most patients in this study were non-severe cases (Figure 5B). TNF-362  $\alpha$  was found to be increases in the LC group, which might be associated with 363 364 the upregulated NK cells.

However, in our proteomics data, we identified two key receptors for IL-6, 365 namely the alpha subunit (IL6R) and the beta subunit (IL6ST) of the 366 interleukin-6 receptor. These two subunits are jointly required to mediate IL-6 367 signal transmission. Overall, LC patients expressed higher IL6ST than SC 368 patients did (Figure 5). Interestingly, IL6R was upregulated in LC patients 369 during the first four weeks followed by a decline thereafter. In SC patients, 370 IL6R expression did not show the substantial change (Figure 5). This 371 difference of IL6R expression trends may reflect transient activation of Th17 372 during the prolonged disease course. We also detected the dynamics of two 373 proteins, transforming growth factor beta-1 protein (TGFB1) and cytosol 374 aminopeptidase (LAP3), which are associated with Treg function. LAP3 is one 375 376 of the surface markers of Treg, and TGFB1 regulated Treg and Th17 (Oida et al., 2003). Similar to IL6ST, LAP3 also kept a higher level in the LC group 377 across the disease course than in SC patients (Figure 5). TGFB1 showed no 378 difference between the SC and LC patients (Figure 5). 379

Taken together, our data showed that NK cell-mediated innate immune and Treg-mediated immunosuppression were both activated in the LC group, while CD3<sup>-</sup>CD56<sup>-</sup>CD16<sup>-</sup> cells were decreased in the LC group, suggesting suppression of B cells which may be associated with decreased antibody level.

385

### 386

### Predictive model for the length of disease course

The above analysis showed that SC and LC patients have different proteomic serological responses during the early phase of COVID-19 when the two groups of patients were clinically indistinguishable during the first few weeks (Figure S1). This raises the possibility of predicting disease course based on proteomic patterns during the early phase. To test this, we built a random forest model using the serum proteomic data collected during the first
three weeks. We included a total of 80 serum samples as a discovery dataset
(Figure 6A) which were randomly divided into two groups: a 66-sample
training dataset (30 patients and 66 samples) and a validation dataset (7
patients and 14 samples). Next, a previously published cohort (39 patients
and 39 samples) (Shen, 2020) was employed as an independent test dataset
from a different clinical center.

To select the most relevant proteins (referred as "feature" in machine 399 learning), we retrieved 174 significantly differentially expressed proteins from 400 the proteomic profiling of SC and LC patients during the first three weeks 401 (Table S3). These proteins were also identified in the independent test 402 dataset. Then 58 features with highest predictive accuracy were prioritized 403 404 from the training set using random forest (4.6.14) (Figure 6A, Figure S7A). After a six-fold cross-validation between the training set and the validation set, 405 a classifier with 35 feature proteins was finalized for classifying LC patients 406 with 100% accuracy in the training set (Figure 6A). The details of the 35 key 407 features are shown in Figure 6B. Intercellular adhesion molecule 1 (ICAM1), 408 409 low affinity immunoglobulin gamma Fc region receptor 3-A (FCGR3A) and immunoglobulin kappa variable 1-16 (IGKV1-16) are the top three ranked 410 proteins, which were significantly regulated in LC patients within the first three 411 weeks (Figure S7B). ICAM1 mediates cell-cell contact and promotes T cell 412 apoptosis (Starke et al., 2010). FCGR3A is involved in antibody-dependent 413 cell-mediated cytotoxicity (ADCC). The elevation of FCGR3A is consistent 414 with the increase of NK cells in the LC group. IGKV1-16 is a part of the 415 variable domain of immunoglobulin light chain, and it is secreted by B cell. 416 IGKV1-16 was down-regulated in the LC group, which might be associated 417 with dysregulation of B cell in the LC as discussed previously. 418

We then applied the model to the independent test cohort from a different 419 420 clinical center. The model correctly classified 32 out of 39 patients with an overall accuracy of 82% (Figure 6C). Due to biosafety issues and the 421 emergency of this pandemic, this study is limited by the sample size. We 422 noticed that the distribution of samples in the different disease stage is 423 different between discovery dataset and test dataset. The numbers of serum 424 425 samples of the discovery dataset are 18, 31 and 31 for the first, second and the third week, respectively. However, the numbers for the test dataset are 21, 426 14 and 4, showing substantially lower proportions in the second and third 427 week. This difference was significant as measured by a two-sides Fisher's 428 exact test (p = 0.0004). The substantially higher number of samples collected 429 in the first week have probably contributed to the difficulty of correct 430 classification by this model. Indeed, the prediction accuracy was 92.9% for the 431 samples collected in the second and third weeks, while the accuracy was only 432 72.2% for the samples collected in the first week. Future application and 433 improvement of this model in larger clinical cohorts are needed. 434

435 **Conclusion** 

COVID-19 patients with short and long disease courses showed no 436 significant difference in clinical symptoms, laboratory tests and response to 437 conventional therapy. Our longitudinal sera proteomic analysis uncovered 438 characteristic host responses in sera of patients with long disease course. 439 including enhanced NK cell-mediated innate immune response and Treg-440 mediated immunosuppression at an early stage. Our data also suggested 441 CD3 CD56 CD16<sup>-</sup> cells might contribute to decreased production of S protein 442 specific antibodies in the patients with a prolonged disease course. Our data 443 suggest modulation of Treg cells may be potential therapeutics for these 444 COVID-19 patients. We also showed that it is possible to predict the disease 445 course of COVID-19 patients based on selected protein levels within the first 446 three weeks after disease onset. The model nevertheless requires further 447 448 validation in independent cohorts.

449

# 450 **ACKNOWLEDGMENTS**

This work is supported by grants from Tencent Foundation (2020), National 451 Natural Science Foundation of China (81972492, 21904107, 81672086), 452 Zhejiang Provincial Natural Science Foundation for Distinguished Young 453 Scholars (LR19C050001), and Hangzhou Agriculture and Society 454 Advancement Program (20190101A04). We thank Drs O.L. Kon, H. Qi, H. Xu, 455 and X. Chang for helpful comments to this study, and Westlake University 456 Supercomputer Center and biomedical research core facilities for assistance 457 in data generation and analysis. 458

459

# 460 **AUTHOR CONTRIBUTIONS**

T.G., S.T., Y.Z. and J.H. designed and supervised the project. S.T., J.H.,
T.M., C. H., S.L., X.X., H.L., L.W., J.D. collected the samples and clinical
data. R.S., Q.X., W.G., M.L., L.Q., H.C., Q.Z., S.L., W.L., H.G., L.L., T.L.,
X.L., X.C., and G.R. conducted proteomic analysis. T.M., Q.X. and R.S.
performed flow cytometry analysis. R.S., Q.X., W.G., T.M., C.H., Y.Z., S.T.
and T.G. interpreted the data with inputs from all co-authors. R.S., Q.X., Y.Z.
and T.G. wrote the manuscript with inputs from co-authors.

# 469 **DECLARATION OF INTERESTS**

- 470 This study is partly supported by Tecent.
- 471

# 472 **REFERENCES**

- 473 Anguela, X.M., Tafuro, S., Roca, C., Callejas, D., Agudo, J., Obach, M., Ribera, A., Ruzo, A., Mann,
- 474 C.J., Casellas, A., et al. (2013). Nonviral-mediated hepatic expression of IGF-I increases Treg
- 475 levels and suppresses autoimmune diabetes in mice. Diabetes *62*, 551-560.

- 476 Brown, J.A., Dorfman, D.M., Ma, F.R., Sullivan, E.L., Munoz, O., Wood, C.R., Greenfield, E.A., and
- Freeman, G.J. (2003). Blockade of programmed death-1 ligands on dendritic cells enhances T cell
  activation and cytokine production. J Immunol *170*, 1257-1266.
- 479 Cao, X. (2020). COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol

480 *20*, 269-270.

- 481 Colaert, N., Barsnes, H., Vaudel, M., Helsens, K., Timmerman, E., Sickmann, A., Gevaert, K., and
- 482 Martens, L. (2011). Thermo-msf-parser: an open source Java library to parse and visualize
- 483 Thermo Proteome Discoverer msf files. J Proteome Res *10*, 3840-3843.
- 484 di Comite, G., Marinosci, A., Di Matteo, P., Manfredi, A., Rovere-Querini, P., Baldissera, E., Aiello,
- 485 P., Corti, A., and Sabbadini, M.G. (2006). Neuroendocrine modulation induced by selective
- 486 blockade of TNF-alpha in rheumatoid arthritis. Ann N Y Acad Sci *1069*, 428-437.
- 487 Eissa, N., Hussein, H., Kermarrec, L., Ali, A.Y., Marshall, A., Metz-Boutigue, M.H., Hendy, G.N.,
- Bernstein, C.N., and Ghia, J.E. (2018). Chromogranin-A Regulates Macrophage Function and the
  Apoptotic Pathway in Murine DSS colitis. J Mol Med (Berl) *96*, 183-198.
- 490 Forman, H.J., Zhang, H., and Rinna, A. (2009). Glutathione: overview of its protective roles,
- 491 measurement, and biosynthesis. Mol Aspects Med *30*, 1-12.
- 492 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., et al.
- 493 (2020). Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue
  494 Samples Using Pressure Cycling Technology. J Proteome Res *19*, 1982-1990.
- 495 Goncalves, C.M., Castro, M.A., Henriques, T., Oliveira, M.I., Pinheiro, H.C., Oliveira, C., Sreenu, V.B.,
- 496 Evans, E.J., Davis, S.J., Moreira, A., *et al.* (2009). Molecular cloning and analysis of SSc5D, a new
- 497 member of the scavenger receptor cysteine-rich superfamily. Mol Immunol *46*, 2585-2596.
- 498 Hu, J., Yan, J., Rao, G., Latha, K., Overwijk, W.W., Heimberger, A.B., and Li, S. (2016). The Duality of
- 499 Fgl2 Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant:
- 500 Therapeutic Potential and Implications. Int Rev Immunol *35*, 325-339.
- 501 Huang, J.e.a. (2020). Long period dynamics of viral load and antibodies for SARS-CoV-2
- 502 infection: an observational cohort study. medRxiv <u>https://doi.org/10.1101/2020.04.22.20071258</u>.
- 503 Ivetic, A., Deka, J., Ridley, A., and Ager, A. (2002). The cytoplasmic tail of L-selectin interacts with
- 504 members of the Ezrin-Radixin-Moesin (ERM) family of proteins: cell activation-dependent 505 binding of Moesin but not Ezrin. J Biol Chem *277*, 2321-2329.
- Kemper, C., Chan, A.C., Green, J.M., Brett, K.A., Murphy, K.M., and Atkinson, J.P. (2003). Activation
  of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature *421*,
  388-392.
- 509 Kimura, A., and Kishimoto, T. (2010). IL-6: regulator of Treg/Th17 balance. Eur J Immunol *40*, 510 1830-1835.
- 511 Kumar, L., and Mattias, E.F. (2007). Mfuzz: a software package for soft clustering of microarray 512 data. Bioinformation *2*, 5-7.
- Li, J., Van Vranken, J.G., Pontano Vaites, L., Schweppe, D.K., Huttlin, E.L., Etienne, C.,
- 514 Nandhikonda, P., Viner, R., Robitaille, A.M., Thompson, A.H., *et al.* (2020). TMTpro reagents: a set
- of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16
- 516 samples. Nat Methods *17*, 399-404.
- 517 Messner, e.a. (2020). Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19
- 518 infection. Cell Systems, <u>https://doi.org/10.1016/j.cels.2020.1005.1012</u>.
- 519 Oida, T., Zhang, X., Goto, M., Hachimura, S., Totsuka, M., Kaminogawa, S., and Weiner, H.L.

- 520 (2003). CD4+CD25- T cells that express latency-associated peptide on the surface suppress
- 521 CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol *170*, 2516-522 2522.
- 523 Ruan, Q., Yang, K., Wang, W., Jiang, L., and Song, J. (2020). Clinical predictors of mortality due to
- 524 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 525 *46*, 846-848.
- Shen, B., *et al.* (2020). Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.
  medRxiv.
- 528 Starke, A., Lindenmeyer, M.T., Segerer, S., Neusser, M.A., Rusi, B., Schmid, D.M., Cohen, C.D.,
- Wuthrich, R.P., Fehr, T., and Waeckerle-Men, Y. (2010). Renal tubular PD-L1 (CD274) suppresses
  alloreactive human T-cell responses. Kidney Int *78*, 38-47.
- 531 Thompson, A., Wolmer, N., Koncarevic, S., Selzer, S., Bohm, G., Legner, H., Schmid, P., Kienle, S.,
- Penning, P., Hohle, C., *et al.* (2019). TMTpro: Design, Synthesis, and Initial Evaluation of a ProlineBased Isobaric 16-Plex Tandem Mass Tag Reagent Set. Anal Chem *91*, 15941-15950.
- 534 To, K.K., Tsang, O.T., Leung, W.S., Tam, A.R., Wu, T.C., Lung, D.C., Yip, C.C., Cai, J.P., Chan, J.M.,
- 535 Chik, T.S., et al. (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples
- and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.Lancet Infect Dis.
- 538 Ueda, Y., Katagiri, K., Tomiyama, T., Yasuda, K., Habiro, K., Katakai, T., Ikehara, S., Matsumoto, M.,
- and Kinashi, T. (2012). Mst1 regulates integrin-dependent thymocyte trafficking and antigen
  recognition in the thymus. Nat Commun *3*, 1098.
- 541 Wojtowicz, A., Gresnigt, M.S., Lecompte, T., Bibert, S., Manuel, O., Joosten, L.A., Rueger, S.,
- 542 Berger, C., Boggian, K., Cusini, A., *et al.* (2015). IL1B and DEFB1 Polymorphisms Increase
- 543 Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. J Infect Dis *211*,544 1646-1657.
- 545 Wu, D., Shu, T., Yang, X., Song, J.-X., Zhang, M., Yao, C., Liu, W., Huang, M., Yu, Y., Yang, Q., *et al.*
- 546 (2020). Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19. National547 Science Review.
- 548 Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons From the
- 549 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases
- 550 From the Chinese Center for Disease Control and Prevention. JAMA.
- 551 Yang, D., Rosenberg, H.F., Chen, Q., Dyer, K.D., Kurosaka, K., and Oppenheim, J.J. (2003).
- Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for
   dendritic cells. Blood *102*, 3396-3403.
- 554 Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., *et al.* (2020).
- 555 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
- 556 China: a single-centered, retrospective, observational study. Lancet Respir Med.
- Yang, Y., Bazhin, A.V., Werner, J., and Karakhanova, S. (2013). Reactive oxygen species in the
  immune system. Int Rev Immunol *32*, 249-270.
- 559 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020).
- 560 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:
- a retrospective cohort study. Lancet *395*, 1054-1062.
- 562 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and
- 563 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of

564 systems-level datasets. Nat Commun *10*, 1523.

565

#### 567 **Table 1. Baseline and progression of CVDTSA cohort**

	non-COVID-19	COVID-19 SC	COVID-19 LC (N=20)		
Baseline Characteristic	(N=35)	(N=17)			
Gender — no. <sup>a</sup> (%)					
male	17 (53.1)	8 (47.1)	11 (55.0)		
female	15 (47.9)	9 (52.9)	9 (45.0)		
Age — yr <sup>b</sup>					
mean ± SD	43.0 ± 18.0	43.2 ± 10.5	49.0 ± 15.4		
median (IQR)	37.5	44	50		
	(28.8-56.0)	(35.0-50.0)	(42.8-55.5)		
range	18-80	27-67	2-84		
Symptoms —no. (%)					
fever	28 (87.6)	10 (58.8)	14 (70.0)		
cough	2 (6.3)	11 (64.7)	15 (75.0)		
diarrhea	1 (3.1)	10 (58.8)	8 (40.0)		
fatigue	1 (3.1)	8 (47.1)	7 (35.0)		
Comorbidities — no. (%)					
hypertension		2 (11.8)	6 (30.0)		
diabetes		0 (0.0)	3 (15.0)		
hepatitis B		2 (11.8)	0 (0.0)		
coronary sclerosis		0 (0.0)	3 (15.0)		
gastrohelcosis		1 (5.9)	0 (0.0)		
psoatic strain		0 (0.0)	1 (5.0)		
chronic gynecologic inflammation		1 (5.9)	0 (0.0)		
gout		0 (0.0)	1 (5.0)		
asthma		0 (0.0)	1 (5.0)		
Treatment— no. (%)					
lopinavir and ritonavir		17 (100.0)	19 (95.0)		
Atomized interferon		17 (100.0)	20 (100.0)		
Arbidol		7 (41.2)	12 (60.0)		
Lianhuaqingwen (Chinese traditional medicine)		15 (88.2)	16 (80.0)		
Ribavirin		0 (0.0)	3 (15.0)		
Hydroxychloroquine		1 (5.9)	3 (15.0)		

<sup>a</sup> no.: number.

<sup>b</sup> yr.: year

## 570 Figure legend

571 **Figure 1. Patients, samples and study workflow. (A)** Baseline

characteristics of the study cohort. The y-axis shows the patient ID, and the x-572 axis displays the length of disease course from onset. The 37 patients are 573 separated into SC (17 patients) and LC (20 patients) groups. Other important 574 information including the virus nucleic acid test results (sputum/throat swab-575 positive/-negative), gender, severity, comorbidity baseline, etc., are shown in 576 the right panel of the figure. The black dots indicate sampling time. More 577 details are provided in Table S1. (B) Workflow for TMT based proteomic 578 analysis in this study. 37 COVID-19 patients and 32 control (Ctrl) patients 579 were included. In total, 224 sera samples were collected and 268 peptide 580 samples including 44 technical replicates were analyzed by TMT 16plex-581 based quantitative proteomics. 582

583 **Figure 2. Complex immunity in the LC patients. (A)** Summary of enriched

immune-related pathways in LC and SC patients across the disease course.

Representative proteins involved in these pathways are also shown. (B) Venn
diagram of differentially expressed proteins between the SC and LC groups
over nine time points and specifically regulated in COVID-19 sera. (C)
Heatmap of 97 dysregulated proteins in the SC and LC groups over nine time
points. (D-E) Expression of protein group 1 and 2 across nine time points. The
y-axis stands for the relative protein expression normalized by z-score. The
pathways and representative participating proteins are shown below the

592 boxplots.

593 Figure 3. Characteristic proteins and pathways in LC patients. (A)

Representative proteins involved in leukocyte migration and IGF/redox
homeostasis are plotted over time. (B) Diagram depicting that major regulated
pathways in the LC patients including leukocytes migration and IGF/redox
homeostasis jointly modulate Treg-mediated immunosuppression.

598 **Figure 4. Flow cytometric analysis of immune cells between SC and LC** 

patients. 22 samples from 17 LC patients and 30 samples from 17 SC
patients were analyzed. (A) Flow cytometric analysis of lymphocytes, CD4+
cells and CD127-CD25+ Treg cells of two representative patients. Bean plots
show the comparison between the two groups. (B) Flow cytometric analysis of
lymphocytes, CD8<sup>+</sup> cells and CD56+CD16+ NK cells of two representative

604 patients. Bean plots show the comparison between the two groups.

**Figure 5. Dynamics of IL6ST, IL6R, LAP3 and TGFB1 in SC and LC** 

- 606 **patients. (A)** Proteins detected by MS-based proteomics. **(B)** Violin plot 607 showed that cytokines detected by antibody-based flow cytometric analysis
- 608 (24 samples from 13 SC patients and 19 samples from 12 LC patients).

### **Figure 6. Machine learning model for predicting disease course. (A)**

- 610 Workflow for machine learning. **(B)** The top 35 key feature proteins selected
- by the machine learning model. **(C)** The validation of the model in an
- 612 independent test dataset.

# 613 **STAR ★ METHODS**

### 614 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER								
Biological Samples										
Serum samples from 37 COVID- 19 patients and 34 non-COVID- 19 patients	Wenzhou Central Hospital	This paper								
Chemicals, Peptides, and Recombinant Proteins										
Triethylammonium bicarbonate buffer (TEAB)	Sigma-Aldrich	Cat # T7408								
Pierce <sup>™</sup> Micro-spin column	Thermo Fisher Scientific	Cat # 89868								
High Select™ Top14 abundant protein depletion resin	Thermo Fisher Scientific	Cat # A36372								
3K MWCO pierce protein concentrators	Thermo Fisher Scientific	Cat # 88521								
Urea	Sigma-Aldrich	Cat # U1250								
Tris (2-carboxyethyl) phosphine (TCEP)	Adamas-beta	Cat # 61820E								
Iodoacetamide (IAA)	Sigma-Aldrich	Cat # l6125								
Trypsin	Hualishi Tech	Cat # HLS TRY001C								
Trifluoroacetic acid (TFA)	Thermo Fisher Scientific	Cat # 85183								
Water	Thermo Fisher Scientific	Cat # W6-4								
Acetonitrile	Thermo Fisher Scientific	Cat # A955-4								
Formic acid (FA)	Thermo Fisher Scientific	Cat # A117-50								
Ammonium hydroxide solution	Sigma-Aldrich	Cat # 221228								
Methanol	Sigma-Aldrich	Cat # 34860								
Critical Commercial Assays										
TMTpro <sup>™</sup> 16plex reagents	Thermo Fisher Scientific	Cat # A44520								
SARS-CoV-2 nucleic acid	Shanghai BioGerm Medical	Cat #								
detection kit	Technology	20200125E								
CD4-PE-Cy7	UB Biotechnology	Cat # UB105441								
CD3-FITC	UB Biotechnology	Cat # UB104411								
CD25-PE	UB Biotechnology	Cat # UB112421								
CD45-PerCP-Cy5.5	UB Biotechnology	Cat # UB109481								
CD127-APC	UB Biotechnology	Cat # UB113451								
CD8-PE	UB Biotechnology	Cat # UB106421								
CD16-PE-Cyanine7	UB Biotechnology	Cat # UB107441								
CD56-PE	UB Biotechnology	Cat # UB108421								
Cytokines detection kit including IL-2/IL-4/IL-5/IL-6/IL- 10/IL-17Α/TNF-α/IFN-v	UB Biotechnology	Cat # UB06PX								

Software and Algorithms								
Xcalibur	Thermo Fisher Scientific	Cat # OPTON- 30965						
Proteome Discoverer Version	Thermo Fisher Scientific	https://www.ther						
2.4.1.15		mofisher.com/hk						
		/en/home/industr						
		ial/mass-						
		spectrometry/liq						
		uid-						
		chromatography						
		-mass-						
		spectrometry-lc-						
		ms/lc-ms-						
		software/multi-						
		omics-data-						
		analysis/proteo						
		me-discoverer-						
		software.html						
R version 3.6.1	R Project	https://www.r-						
		project.org						
Ingenuine pathway analysis	Kramer et al., 2014	https://www.qiag						
(version 51963813)		en.com/cn/						
Kaluza analysis soft version 2.1	Beckman coulter life sciences	Cat # A82959						
NovoExpress version 1.4.1	Agilent Bio	https://www.ace						
		abio.com/produc						
		ts/novoexpress-						
		software/						
Other								
SOLAµ	Thermo Fisher Scientific	Cat # 62209-001						
ACQUITY UPLC Systems with	Waters Corporation	Cat #						
2D LC Technology		186015001						
ACQUITY BEH C18 column, 2.1	Waters Corporation	Cat #						
× 100 mm, 1.7 μm		186008316						
ACQUITY BEH Amide column,	Waters Corporation	Cat #						
2.1 × 100 mm, 1.7 μm		186008315						

# 616 **RESOURCE AVAILABILITY**

#### 617 Lead contact

618 Further information should be directed to and will be fulfilled by the Lead

619 Contact Tiannan Guo (guotiannan@westlake.edu.cn).

### 621 Materials Availability

622 This study did not generate new unique reagents.

# 623624 Data Availability

All data are available in the manuscript or the supplementary material. The proteomics data are deposited in ProteomeXchange Consortium (https://www.iprox.org/). Project ID: IPX0002170000.

#### 628 629

620

# 630 EXPERIMENTAL MODEL AND SUBJECT DETAILS

### 631 **Patients and sera samples**

We procured 72 patients in this study, including 37 COVID-19 patients 632 whose sputa or throat swabs were tested positive for SARS-CoV-2 633 according to the manufacturer's instructions (Shanghai BioGerm Medical 634 Technology Co., LTD, Shanghai, China). According to the Chinese 635 Government Diagnosis and Treatment Guideline (Trial 4th version) (Shen, 636 2020), these 37 COVID-19 patients include 35 typical cases and two severe 637 cases. We have also procured 35 non-COVID-19 patients showing similar 638 flu-like clinical symptoms to COVID-19 patients with negative nucleic acid 639 testing for SARS-CoV-2. More details of these patients are provided in 640 Figure 1A and Table S1. 641

We defined the disease onset as the day when the patient manifests clinical symptoms, while the disease recovery as the day when nucleic acid test of sputa or throat swab turns negative, and negative for the second test after a minimal interval of 24 hours, the same test is still negative. The disease course was thus defined as the period between disease onset and disease recovery.

Totally 224 sera samples from these patients were collected 648 longitudinally for proteomics analysis (Figure 1B, Table S1). Sampling was 649 performed in the early morning before diet using serum separation tubes 650 (BD, USA). The blood was clotted for about 30 min at room temperature, 651 and then centrifuged at 1000 g for ten min for serum sample collection. This 652 study has been registered in the Chinese Clinical Trial Registry with an ID of 653 654 ChiCTR2000031699. This study has been approved by the Ethical/Institutional Review Board of Wenzhou Central Hospital and Westlake 655 University. Contents from patients were waived by the boards. 656 657

### 658 **METHOD DETAILS**

659

#### 660 **Proteome analysis**

Serum samples were prepared as previously described (Shen, 2020). 661 Briefly, serum samples were firstly inactivated and sterilized at 56 °C for 30 662 mins. For proteomic study, 4 µL of serum was used for each sample. The 663 serum was firstly depleted of 14 high abundant serum proteins using a 664 human affinity depletion kit (Thermo Fisher Scientific™, San Jose, USA). 665 After depletion, the serum solution was concentrated into 50 µL through a 3k 666 MWCO filtering unit (Thermo Fisher Scientific™, San Jose, USA) according 667 to manufacturer. And then was mixed with 500 µL 8 M urea (Sigma) and 668 concentrated into 50 µL. Then proteins were reduced and alkylated with 10 669 mM tris (2-carboxyethyl) phosphine (TCEP, Sigma) and 40 mM 670 iodoacetamide (IAA), respectively. Proteins were submitted to two times of 671 tryptic digestion (enzyme to protein ratio: 1:20; Hualishi Tech. Ltd, Beijing, 672 China). The digestion was then stopped with 1% trifluoroacetic (TFA) 673 (Thermo Fisher) to pH 2-3 to stop the reaction, and peptides were subjected 674 to C18 (Thermo Fisher) desalting. 675

TMT 16-plex (Thermo Fisher) reagents were applied to label the digested 676 peptides. The TMT labeled samples were further fractionated along a 2 hr 677 basic pH reverse phase LC gradient using a Dinex Ultimate 3000 UHPLC 678 (Thermo Fisher) (Li et al., 2020). LC-MS/MS analysis was performed using 679 the Easy-nLC<sup>™</sup> 1200 nanoLC-MS/MS system (Thermo Fisher) or a Dinex 680 Ultimate 3000 UHPLC coupled to a Q Exactive HF or HF-X (Thermo Fisher). 681 along a 60 min LC gradient at a flowrate of 300 nL/min as described 682 previously (Gao et al., 2020; Shen, 2020). To reach comparable proteomic 683 depth, the fractionated samples were combined into 30 fractions for analysis 684 in QE-HF instruments and 26 for QE-HFX instruments. 685

686 687

#### Database search and statistical analysis

MS data was performed using Proteome Discoverer (Version 2.4.1.15, 688 Thermo Fisher) (Colaert et al., 2011) search engine against the human 689 690 protein database downloaded from UniProt (version 02/01/2020; 164,930 sequences), with a precursor ion mass tolerance of 10 ppm and fragment ion 691 mass tolerance of 0.02 Da. Please see previous paper (Shen, 2020) for 692 detailed parameters of the database searching. Briefly, TMT pro-plex labels 693 to lysine and N-terminus, and carbamidomethylation of cysteine were set as 694 static modifications. A cut-off criterion of a q-value of 0.01, corresponding to 695 a 1% false-discovery rate (FDR) was set for the filtered of identified peptides 696 with highly confident peptide hits. 697

After filtering 80% missing rate proteins, 2700 proteins used for
 differential expression analysis based on |log2(FC)| and two-sided unpaired
 Welch's t test. The created missing values were imputed with zero.

701

#### 702 Pathway analysis

For the pathway enrichment analysis, firstly, four databases including
KEGG pathway, GO biological processes, Reactome gene sets and
immunologic signatures were used for immune characterization analysis on
the Metascape web-based platform (Zhou et al., 2019). IPA was then used
to look at the pathways for differentially expressed proteins.

708 709 **Statis** 

### 9 Statistical analysis

Two-sided unpaired Welch's t test was performed for each pair of
comparing groups. The one-way analysis of variance (ANOVA) was used to
performed among nine time points. Adjusted p values were calculated using
Benjamini & Hochberg correction.

714

### 715 Machine learning

The machine learning was performed using the R package randomForest 716 (version 4.6.14) as described previously with some modifications (Shen, 717 2020) as described briefly in the following. The discovery dataset was divided 718 into two parts, *i.e.* the training set and the validation set. We optimized the key 719 random forest parameters including the cutoff values for decrease mean 720 accuracy, cross-validation fold, and the number of trees. Input protein features 721 were selected based on the mean decrease accuracy cutoff. For the 722 optimized model, the minimal mean decrease accuracy of protein features 723 was 2, the mtry was set as 13, and 800 trees were built. Six-fold cross 724 validation was performed and this was repeated 100 times. 725

726

### 727 Flow cytometry analysis

Peripheral blood samples from EDTA anticoagulants were incubated with 728 mixture antibodies including CD4-PE-Cy7 (UB105441, UB Biotechnology Co., 729 Ltd, Hangzhou, China), CD3-FITC (UB104411), CD25-PE (UB112421), 730 CD45-PerCP-Cy5.5 (UB109481), CD127-APC (UB113451) and a kit 731 (UB06PX) for cytokines detection including IL-2/IL-4/IL-5/IL-6/IL-10/IL-732  $17A/TNF-\alpha/IFN-\gamma$  for 15 min at room temperature. Double negative control 733 734 and single-stain controls were prepared by normal samples, and were used to calculate a compensation matrix. Sample acquisition was performed on a 735 Gallios (Beckman Coulter) cytometer equipped. Final analysis and graphical 736 output were performed using NovoExpress software (Agilent Bio). 737 738

# 739 SUPPLEMENTARY FIGURE LEGEND

Figure S1. Correlation analysis between the SC and LC group based on 740 clinical data, Related to Figure 1. (A) Boxplot of patient ages. Ctrl (N=35), 741 SC (N=17) and LC(N=20). (B) Heatmap shows medication history in SC and 742 LC groups. The column set on the right represents the drugs and relevant p 743 value showing medication difference between the two groups (two-sided 744 Fisher. test). (C) Comparison of blood test results between SC (N=17) and LC 745 (N=15) patients. Boxplots display the blood biochemistry tests based on 746 samples collected on the first day in the hospital. 747 Figure S2. Quality assessment of proteomics data. Related to Figure 1. 748 (A) Batch design of proteomic analysis. All 268 peptide samples are randomly 749 separated into 18 batches for TMTpro labeling and MS analysis. (B) The 750 median technical CV of the proteomics data is calculated by the identified 751 proteins in 44 technical replicates. 752 Figure S3. Pathway enrichment analysis at nine time points using 753 differentially expressed proteins between the SC and LC group, Related 754 to Figure 2. Pathways were enriched using Metascape. The pathways in the 755 blue box are not directedly related to immunity. 756 Figure S4. The dynamic expression of proteins across the entire disease 757 course between SC and LC, Related to Figure 2. The x-axis shows the 758 week index, while the y-axis denotes protein expression ratio from the TMT 759 experiment. Pair-wise comparison of each proteins in the two patient groups 760 was performed with student's *t* test. \*, p < 0.05; \*\*, p < 0.01. 761 Figure S5. Eight clusters of proteins showing temporal dynamics by 762 Mfuzz analysis in the SC and LC group, Related to Figure 4. Proteins 763 detected in SC (A) and LC (B) are grouped into eight clusters with different 764 quantitative patterns over the disease course. ANOVA analysis was performed 765 in each cluster (the cutoff of the adjusted p value (BH adjust) was 0.05). (C) 766 Upset plots shows the overlapping protein clusters selected by Mfuzz. 767 Figure S6. Flow cytometric analysis of lymphocytes, CD3- cells, Related 768 to Figure 4. 22 samples from 17 LC patients and 30 samples from 17 SC 769 patients were measured and analyzed. (A) Results of lymphocytes, CD3-770 cells, i.e. P14 (SC) and P15 (LC). (B) Bean plots show the comparison of cell 771 populations between patient groups. (C) Violin plots show cytokines detected 772 by antibody-based flow cytometric analysis (24 samples from 13 SC patients 773 and 19 samples from 12 LC patients). The y-axis shows the intensity of each 774 cytokine. 775 Figure S7. 58 key feature proteins and the expression of top three 776 proteins, ICAM1, FCGR3A and IGKV1-16. Related to Figure 6 (A) 58 777 features ranking according to mean decrease accuracy. (B) Protein 778 expression of ICAM1, FCGR3A and IGKV1-16 between SC and LC groups in 779 discovery dataset test dataset, respectively. 780 781





Figure 3











798 Figure 6





805 Figure S2

$\sim$	B1	B2	B3	B4	B5	B6	B7	B8	B9	B10	B13	B14	B15	B16	B17	B18	B19	B20
126	Pool 1	Pool 1	Pool 2	Pool 2	Pool 2	Pool 2	Pool 1	Pool 1	Pool 1									
127C	P23_2	P5_2	P25_1	P29_2	P13_1	P26_1	P7_1	P2_2	P34_4	Pool 2	Pool 2	P10_1B	P22_1B	P23_7	P18_4	P29_5	P26_5	P33_8
127N	P23_3	P5_3	P25_2	P29_3	P13_2	P26_2	P7_2	P2_3	P35_7	P33_7	P2_2B	P10_2C	P22_2B	P23_8	P5_7	P29_6	P28_5	P33_9
128C	P23_5	P9_4	P25_4	P29_4	P13_3	P26_3	P7_3	P27_2	P35_6	P33_5	P2_3B	P10_3B	P22_3B	P20_8	P5_9	P29_8	P28_4	P33_10
128N	P20_3	P17_2	P8_1	P30_1	P10_1	P21_1	P32_2	P27_3	P36_7	P33_6	P2_4B	P10_4	P22_4	P20_9	P8_3B	P30_5	P28_7	P16_4
129C	P20_4	P17_3	P8_2	P30_2	P10_2	P21_2	P32_3	P27_4	P36_5	P10_6	P2_5B	P10_6B	P22_9	P6_6	P25_5	P30_6	P7_5	P16_5
129N	P20_5	P17_4	P8_3	P30_3	P10_3	P21_3	P32_4	P16_1	P37_6	P10_2B	P2_6C	P21_1B	P24_1B	P6_7	P25_6	P15_4	P7_6	P16_6
130C	P6_2	P22_1	P3_2	P18_1	P14_1	P24_1	P1_2	P16_2	Ctrl_1	P2_4	P2_7	P21_2B	P24_2B	P6_9	P25_8	P15_5	P7_8	P16_8
130N	P6_3	P22_2	P3_3	P18_2	P14_2	P24_2	P1_3	P16_3	P2_6	P2_6B	P32_2B	P21_3B	P24_3B	P31_4	P8_4	P15_6	P12_4	P19_6
131C	P6_4	P22_3	P3_4	P18_3	P14_3	P24_3	P12_1	P19_2	P36_7B	P2_5	P32_3B	P21_4	P24_4	P31_5	P8_5	P15_8	P12_5	P19_7
131N	P31_1	Ctrl_5	P11_1	P15_1	Ctrl_12	P28_1	P12_2	P19_3	P7_3B	Ctrl_2B	P32_4B	P21_5	P24_5	P31_7	P8_7	P13_4	P12_6	P19_9
132C	P31_2	Ctrl_16	P11_2	P15_2	Ctrl_35	P28_2	P12_3	P19_4	P18_2B	Ctrl_6B	P32_6	P21_6	P24_6	P35_9	P11_4	P13_6	P12_8	P2_2C
132N	P31_3	Ctrl_32	P11_3	P15_3	Ctrl_34	P28_3	Ctrl_18	Ctrl_30	P22_3B	Ctrl_26B	P32_8	P1_5	P24_8	P36_8	P11_5	P13_8	P9_5	P4_6
133C	Ctrl_6	Ctrl_27	Ctrl_3	Ctrl_4	Ctrl_22	Ctrl_10	Ctrl_11	Ctrl_23	Ctrl_14	P21_3C	Ctrl_6B	P1_6	P3_5	P36_9	P11_6	P14_4	P12_3B	P4_8
133N	Ctrl_13	Ctrl_17	Ctrl_24	Ctrl_25	Ctrl_29	Ctrl_36	Ctrl_8	Ctrl_9	Ctrl_15	P25_4B	Ctrl_13B	P1_8	P3_7	P20_5B	P11_8	P14_5	P37_9	P22_5
134N	Ctrl_31	Ctrl_33	Ctrl_26	Ctrl_21	Ctrl_7	Ctrl_19	Ctrl_28	Ctrl_20	Ctrl_1B	P19_4B	Ctrl_31B	Ctrl_27B	P3_8	P10_3C	P5_6	P14_7	P34_7	P16_2B



















821



Page 35 of 36

822 Figure S7

Α

